Alx Oncology Stock Today

ALXO
 Stock
  

USD 10.21  0.47  4.40%   

Market Performance
0 of 100
Odds Of Distress
Less than 24
Alx Oncology is selling for 10.21 as of the 28th of November 2022. This is a -4.4 percent decrease since the beginning of the trading day. The stock's open price was 10.68. Alx Oncology has about a 24 % chance of experiencing some form of financial distress in the next two years of operation but has generated negative returns over the last 90 days. Equity ratings for Alx Oncology Holdings are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 8th of December 2020 and ending today, the 28th of November 2022. Click here to learn more.
Fiscal Year End
December
IPO Date
17th of July 2020
Category
Healthcare
ISIN
US00166B1052
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. The company was founded in 2015 and is headquartered in South San Francisco, California. Alx Oncology operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 40.5 M outstanding shares of which 4.4 M shares are presently shorted by private and institutional investors with about 29.05 trading days to cover. More on Alx Oncology Holdings
Follow Valuation Odds of Bankruptcy
Check how we calculate scores

Alx Oncology Stock Highlights

Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Alx Oncology's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Alx Oncology or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
Alx Oncology generated a negative expected return over the last 90 days
Alx Oncology has high historical volatility and very poor performance
The company reported the previous year's revenue of 527 K. Net Loss for the year was (110.46 M) with profit before overhead, payroll, taxes, and interest of 107 K.
Alx Oncology Holdings currently holds about 313.37 M in cash with (80.02 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 7.69.
Average Analyst Recommendation
Analysts covering Alx Oncology report their recommendations after researching Alx Oncology's financial statements, talking to executives and customers, or listening in on Alx Oncology's conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Alx Oncology Holdings. The Alx Oncology consensus assessment is calculated by taking the average forecast from all of the analysts covering Alx Oncology.
Macroaxis Advice
Unlike general analyst consensus, Macroaxis buy hold or sell recommendation is provided in the context of your current investment horizon and risk tolerance. The advice algorithm takes into account all of Alx Oncology's available fundamental, technical, and predictive indicators. Your current horizon is 90 days - details
Alx Oncology Holdings (ALXO) is traded on NASDAQ Exchange in USA and employs 52 people. The company currently falls under 'Small-Cap' category with current market capitalization of 433.75 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Alx Oncology's market, we take the total number of its shares issued and multiply it by Alx Oncology's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities. Alx Oncology Holdings conducts business under Healthcare sector and is part of Biotechnology industry. The entity has 40.5 M outstanding shares of which 4.4 M shares are presently shorted by private and institutional investors with about 29.05 trading days to cover. Alx Oncology Holdings currently holds about 313.37 M in cash with (80.02 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 7.69.
Check Alx Oncology Probability Of Bankruptcy
Ownership
Alx Oncology Holdings retains a total of 40.5 Million outstanding shares. The majority of Alx Oncology Holdings outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Alx Oncology Holdings to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Alx Oncology. Please pay attention to any change in the institutional holdings of Alx Oncology Holdings as this could imply that something significant has changed or about to change at the company. Also note that nearly one million six hundred twenty thousand invesors are currently shorting Alx Oncology expressing very little confidence in its future performance.

Ownership Allocation (%)

Check Alx Oncology Ownership Details

Alx Oncology Stock Price Odds Analysis

Proceeding from a normal probability distribution, the odds of Alx Oncology jumping above the current price in 90 days from now is about 88.11%. The Alx Oncology Holdings probability density function shows the probability of Alx Oncology stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days the stock has a beta coefficient of 1.3771. This suggests as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Alx Oncology will likely underperform. Additionally, the company has a negative alpha, implying that the risk taken by holding this instrument is not justified. Alx Oncology Holdings is significantly underperforming DOW.
  Odds Below 10.21HorizonTargetOdds Above 10.21
11.83%90 days
 10.21 
88.11%
Based on a normal probability distribution, the odds of Alx Oncology to move above the current price in 90 days from now is about 88.11 (This Alx Oncology Holdings probability density function shows the probability of Alx Oncology Stock to fall within a particular range of prices over 90 days) .

Alx Oncology Stock Institutional Holders

Institutional Holdings refers to the ownership stake in Alx Oncology that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Alx Oncology's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Alx Oncology's value.
InstituionSecurity TypeTotal SharesValue
Zurcher Kantonalbank Zurich CantonalbankCommon Shares61113 K
Zurcher Kantonalbank Zurich CantonalbankCommon Shares67550 K
Wells Fargo CompanyPut Options1000K
View Alx Oncology Diagnostics

Alx Oncology Holdings Risk Profiles

Investors will always prefer to have the highest possible return on investment while minimizing volatility. Alx Oncology market risk premium is the additional return an investor will receive from holding Alx Oncology long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Alx Oncology. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Although Alx Oncology's alpha and beta are two of the key measurements used to evaluate Alx Oncology's performance over the market, the standard measures of volatility play an important role as well.

Alx Oncology Stock Against Markets

Picking the right benchmark for Alx Oncology stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Alx Oncology stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Alx Oncology is critical whether you are bullish or bearish towards Alx Oncology Holdings at a given time.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Alx Oncology without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Insider Screener Now

   

Insider Screener

Find insiders across different sectors to evaluate their impact on performance
All  Next Launch Module

Invested in Alx Oncology Holdings?

The danger of trading Alx Oncology Holdings is mainly related to its market volatility and company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Alx Oncology is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Alx Oncology. The Shape ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Alx Oncology Holdings is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Please continue to Trending Equities. You can also try Watchlist Optimization module to optimize watchlists to build efficient portfolio or rebalance existing positions based on mean-variance optimization algorithm.

Complementary Tools for analysis

When running Alx Oncology Holdings price analysis, check to measure Alx Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Alx Oncology is operating at the current time. Most of Alx Oncology's value examination focuses on studying past and present price action to predict the probability of Alx Oncology's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Alx Oncology's price. Additionally, you may evaluate how the addition of Alx Oncology to your portfolios can decrease your overall portfolio volatility.
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Go
Analyst Recommendations
Analyst recommendations and target price estimates broken down by several categories
Go
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Go
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Go
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Go
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Go
Analyst Recommendations
Analyst recommendations and target price estimates broken down by several categories
Go
Analyst Recommendations
Analyst recommendations and target price estimates broken down by several categories
Go
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Go
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Go
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Go
Is Alx Oncology's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Alx Oncology. If investors know Alx Oncology will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Alx Oncology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
435.3 M
Quarterly Revenue Growth YOY
(1.00) 
Return On Assets
(0.22) 
Return On Equity
(0.36) 
The market value of Alx Oncology Holdings is measured differently than its book value, which is the value of Alx Oncology that is recorded on the company's balance sheet. Investors also form their own opinion of Alx Oncology's value that differs from its market value or its book value, called intrinsic value, which is Alx Oncology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Alx Oncology's market value can be influenced by many factors that don't directly affect Alx Oncology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Alx Oncology's value and its price as these two are different measures arrived at by different means. Investors typically determine Alx Oncology value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Alx Oncology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.